Zouali Els-07 Tolerance-07
... autoimmune thyroiditis (with thyroglobulin) and myasthenia gravis in Lewis rats (with acetylcholine receptor). Work from animal models has been extended into human clinical trials (multiple sclerosis, rheumatoid arthritis, diabetes, uveitis and allergy) with variable degrees of success. For example, ...
... autoimmune thyroiditis (with thyroglobulin) and myasthenia gravis in Lewis rats (with acetylcholine receptor). Work from animal models has been extended into human clinical trials (multiple sclerosis, rheumatoid arthritis, diabetes, uveitis and allergy) with variable degrees of success. For example, ...
The Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression
... regulate IDO expression. Toll-like receptors (TLRs), tumor necrosis factor superfamily members (TNFRs), interferon beta receptor (IFNBR), the interferon gamma receptor (IFNGR), transforming growth factor beta receptors (TGFBRs) and the aryl hydrocarbon receptor (AhR) all can activate signaling mecha ...
... regulate IDO expression. Toll-like receptors (TLRs), tumor necrosis factor superfamily members (TNFRs), interferon beta receptor (IFNBR), the interferon gamma receptor (IFNGR), transforming growth factor beta receptors (TGFBRs) and the aryl hydrocarbon receptor (AhR) all can activate signaling mecha ...
The Canadian Lung Cancer Conference 2016
... They Make a Difference in Lung Cancer?” She reviewed the evolution of radiation therapy over the last several decades and explained the therapeutic ratio: the ratio of local control relative to toxicity. Although disease control continues to increase, treatment intensification has increased as well, ...
... They Make a Difference in Lung Cancer?” She reviewed the evolution of radiation therapy over the last several decades and explained the therapeutic ratio: the ratio of local control relative to toxicity. Although disease control continues to increase, treatment intensification has increased as well, ...
Immune sys ch 43 notes
... Antimicrobial Peptides and Proteins • Peptides and proteins function in innate defense by attacking microbes directly or ...
... Antimicrobial Peptides and Proteins • Peptides and proteins function in innate defense by attacking microbes directly or ...
Immunology
... TH0 cells can develop into either TH1 or TH2 cells, with IFN- and IL-12 favouring the development of TH1 and IL-4 and IL10 favouring the development of TH2. TH1 cells secrete IFN-, whereas TH2 cells secrete IL-4, although both secrete several other cytokines (IL-3, GMCSF, TNF-) equally well. TH1 ...
... TH0 cells can develop into either TH1 or TH2 cells, with IFN- and IL-12 favouring the development of TH1 and IL-4 and IL10 favouring the development of TH2. TH1 cells secrete IFN-, whereas TH2 cells secrete IL-4, although both secrete several other cytokines (IL-3, GMCSF, TNF-) equally well. TH1 ...
Ppoint - Dr. Stuart White
... In the hopeless Juvenile Diabetic condition there is now evidence of hope through understanding that comes from watching “Honeymoon period” follows initial insulin dependency showing an initial beta cell proliferation and corresponding decrease in insulin dependency – then a return to complete i ...
... In the hopeless Juvenile Diabetic condition there is now evidence of hope through understanding that comes from watching “Honeymoon period” follows initial insulin dependency showing an initial beta cell proliferation and corresponding decrease in insulin dependency – then a return to complete i ...
receptors - EuroBiotech Project
... •The extravascular compartment consists of a stroma of a fibrous connective tissue , stromal cells (fibroblasts, fat cells, numerous plasma cells) and pluripotent stem cells (1 per 104 stromal cells). •The epithelial cells of the capillary sinuses contain narrow openings that permit the mature red a ...
... •The extravascular compartment consists of a stroma of a fibrous connective tissue , stromal cells (fibroblasts, fat cells, numerous plasma cells) and pluripotent stem cells (1 per 104 stromal cells). •The epithelial cells of the capillary sinuses contain narrow openings that permit the mature red a ...
The Complement System
... “Punishment Model” – strong synapses effectively drive postsynaptic responses and punish weaker synapses by eliminating them ...
... “Punishment Model” – strong synapses effectively drive postsynaptic responses and punish weaker synapses by eliminating them ...
A novel adenosine A receptor antagonist optimized for high potency
... We first explored the expression of the four adenosine receptors in primary human immune cells. A2A receptor was the main adenosine receptor expressed by CD4 and CD8 T lymphocytes and monocytes, and the only one in mature monocyte-derived dendritic cells and NK cells. A2B receptor was poorly detecte ...
... We first explored the expression of the four adenosine receptors in primary human immune cells. A2A receptor was the main adenosine receptor expressed by CD4 and CD8 T lymphocytes and monocytes, and the only one in mature monocyte-derived dendritic cells and NK cells. A2B receptor was poorly detecte ...
Confronting the Challenge of Respiratory Tract Infections
... H. Influenzae H. influenzae nonencapsulated: nontypeable H. influenzae encapsulated: serotypes a, b, c, d, e, f H. influenzae serotype b (Hib) polysacharide vaccine H. influenzae serotype b (Hib) polysacharide conjugate vaccine ...
... H. Influenzae H. influenzae nonencapsulated: nontypeable H. influenzae encapsulated: serotypes a, b, c, d, e, f H. influenzae serotype b (Hib) polysacharide vaccine H. influenzae serotype b (Hib) polysacharide conjugate vaccine ...
David E. Elder, MB, CHB, FRCPA
... including any warranties as to accuracy, comprehensiveness, or currency of the content of this work. This work is no substitute for individual patient assessment based upon healthcare professionals’ examination of each patient and consideration of, among other things, age, weight, gender, current or ...
... including any warranties as to accuracy, comprehensiveness, or currency of the content of this work. This work is no substitute for individual patient assessment based upon healthcare professionals’ examination of each patient and consideration of, among other things, age, weight, gender, current or ...
Neutrophils diminish T-cell immunity to foster gastric cancer
... tumour cells by releasing antimicrobial and cytotoxic contents that are prestored in their granules. Neutrophils can induce apoptosis in tumour cells and reduce tumour growth when administrated into tumour-bearing animals. Neutrophils are regarded as important effector cells for monoclonal antibody ...
... tumour cells by releasing antimicrobial and cytotoxic contents that are prestored in their granules. Neutrophils can induce apoptosis in tumour cells and reduce tumour growth when administrated into tumour-bearing animals. Neutrophils are regarded as important effector cells for monoclonal antibody ...
Gene Expression Measurement of Immuno
... tumors, the lymphocyte infiltrates appear to be similar, whereas one tumor appears to be mounting a significant type I interferon response, which is not as apparent in the other tumor. In the series of DLBCL samples, gene expression distribution was consistent between the two panels for most of the ...
... tumors, the lymphocyte infiltrates appear to be similar, whereas one tumor appears to be mounting a significant type I interferon response, which is not as apparent in the other tumor. In the series of DLBCL samples, gene expression distribution was consistent between the two panels for most of the ...
TCR ζ-CHAIN DOWNREGULATION: CURTAILING AN EXCESSIVE
... Figure 1 | Activation and attenuation signals controlling TCR-mediated T-cell function. Following T-cell receptor (TCR) and CD28 co-receptor engagement, SRC protein tyrosine kinases (PTKs) — LCK and FYN — are activated and phosphorylate the ζ- and ε-chains of the TCR at tyrosine residues that are pr ...
... Figure 1 | Activation and attenuation signals controlling TCR-mediated T-cell function. Following T-cell receptor (TCR) and CD28 co-receptor engagement, SRC protein tyrosine kinases (PTKs) — LCK and FYN — are activated and phosphorylate the ζ- and ε-chains of the TCR at tyrosine residues that are pr ...
Jun N-terminal kinase activity and early growth
... failure, and cancer susceptibility. At the cellular level, FA cells are hypersensitive to DNA cross-linking agents such as mitomycin C (MMC) or diepoxybutane.1,2 FA is a genetically heterogeneous disease, comprising at least 8 complementation groups: FA-A, -B, -C, -D1, -D2, -E, -F and -G, the FA-A g ...
... failure, and cancer susceptibility. At the cellular level, FA cells are hypersensitive to DNA cross-linking agents such as mitomycin C (MMC) or diepoxybutane.1,2 FA is a genetically heterogeneous disease, comprising at least 8 complementation groups: FA-A, -B, -C, -D1, -D2, -E, -F and -G, the FA-A g ...
Review Article Mechanisms of action of CD20 antibodies
... Only those SNPs are listed that directly influence IgG binding. In case of FCGR2C, the FCGR2C-ORF genotype is due to a G > C mutation at position −386 that results in functional expression of FcγRIIc. 2FcγRIIIb is a GPI-linked membrane protein that is shown to signal via FcγRIIa and / or CR3. ...
... Only those SNPs are listed that directly influence IgG binding. In case of FCGR2C, the FCGR2C-ORF genotype is due to a G > C mutation at position −386 that results in functional expression of FcγRIIc. 2FcγRIIIb is a GPI-linked membrane protein that is shown to signal via FcγRIIa and / or CR3. ...
PowerPoint 프레젠테이션
... 5. Non-specific vs. antigen specific For example, regarding the cytokine production ; Drakes et al., Infect Immunol, 2004 : human DC produce IL-10, not IL-12p70 Mohamadzadeh et al., PNAS, 2005 : human DC, produce IL-12p70, but not IL-12 ...
... 5. Non-specific vs. antigen specific For example, regarding the cytokine production ; Drakes et al., Infect Immunol, 2004 : human DC produce IL-10, not IL-12p70 Mohamadzadeh et al., PNAS, 2005 : human DC, produce IL-12p70, but not IL-12 ...
Slide 1
... – Multiple and co-existent mechanisms/phenotypes – Efficacy of new drugs cannot be predicted from preclinical models nor from currently defined patient characteristics – lack of biomarkers that enable us to effectively track disease progression or the impact of a novel therapy on disease in clinical ...
... – Multiple and co-existent mechanisms/phenotypes – Efficacy of new drugs cannot be predicted from preclinical models nor from currently defined patient characteristics – lack of biomarkers that enable us to effectively track disease progression or the impact of a novel therapy on disease in clinical ...
Immune Response and Interventions
... specific pathogens studied in the programme “Infection Research”; (3) development of strategies to strengthen effector T cells and T cell-dependent B cell responses or to modulate Tregs. Research aim 2: Unravel the immune evasion mechanisms operative during infection Pathogens have developed various ...
... specific pathogens studied in the programme “Infection Research”; (3) development of strategies to strengthen effector T cells and T cell-dependent B cell responses or to modulate Tregs. Research aim 2: Unravel the immune evasion mechanisms operative during infection Pathogens have developed various ...
What is plasmapheresis?
... disease, primarily affects the lungs and kidneys, leading to rapid renal failure. The hallmark of this disorder is the presence of anti-glomerular basement membrane (anti-GBM) antibodies. This antibody is directed toward the α3 chain of type IV collagen, which is found in the basement membrane of re ...
... disease, primarily affects the lungs and kidneys, leading to rapid renal failure. The hallmark of this disorder is the presence of anti-glomerular basement membrane (anti-GBM) antibodies. This antibody is directed toward the α3 chain of type IV collagen, which is found in the basement membrane of re ...
Cancer immunotherapy
Cancer immunotherapy (immuno-oncology) is the use of the immune system to treat cancer. Immunotherapies fall into three main groups: cellular, antibody and cytokine. They exploit the fact that cancer cells often have subtly different molecules on their surface that can be detected by the immune system. These molecules, known as cancer antigens, are most commonly proteins, but also include molecules such as carbohydrates. Immunotherapy is used to provoke the immune system into attacking the tumor cells by using these antigens as targets.Antibody therapies are the most successful immunotherapy, treating a wide range of cancers. Antibodies are proteins produced by the immune system that bind to a target antigen on the cell surface. In normal physiology the immune system uses them to fight pathogens. Each antibody is specific to one or a few proteins. Those that bind to cancer antigens are used to treat cancer. Cell surface receptors are common targets for antibody therapies and include the CD20, CD274, and CD279. Once bound to a cancer antigen, antibodies can induce antibody-dependent cell-mediated cytotoxicity, activate the complement system, or prevent a receptor from interacting with its ligand, all of which can lead to cell death. Multiple antibodies are approved to treat cancer, including Alemtuzumab, Ipilimumab, Nivolumab, Ofatumumab, and Rituximab.Cellular therapies, also known as cancer vaccines, usually involve the removal of immune cells from the blood or from a tumor. Immune cells specific for the tumor are activated, cultured and returned to the patient where the immune cells attack the cancer. Cell types that can be used in this way are natural killer cells, lymphokine-activated killer cells, cytotoxic T cells and dendritic cells. The only cell-based therapy approved in the US is Dendreon's Provenge, for the treatment of prostate cancer.Interleukin-2 and interferon-α are examples of cytokines, proteins that regulate and coordinate the behaviour of the immune system. They have the ability to enhance anti-tumor activity and thus can be used as cancer treatments. Interferon-α is used in the treatment of hairy-cell leukaemia, AIDS-related Kaposi's sarcoma, follicular lymphoma, chronic myeloid leukaemia and malignant melanoma. Interleukin-2 is used in the treatment of malignant melanoma and renal cell carcinoma.